To study impact of treatment with Rosuvastatin versus Atorvastatin on 25 hydroxy Vitamin D concentrations among adult Indian men- a randomized control trial.
Atorvastatin
Vitamin D
cholesterol
rosuvastatin
statins
Journal
Indian journal of pharmacology
ISSN: 1998-3751
Titre abrégé: Indian J Pharmacol
Pays: India
ID NLM: 7902477
Informations de publication
Date de publication:
Historique:
entrez:
7
12
2020
pubmed:
8
12
2020
medline:
23
11
2021
Statut:
ppublish
Résumé
Dyslipidemias are on the rise and are increasingly being treated with statins. As the metabolism of cholecalciferol and cholesterol are interrelated, reduction in cholesterol synthesis by statins is likely to affect Vitamin D status. (1) The aim is to study the effect of treatment with statins (Atorvastatin/Rosuvastatin) on 25-hydroxy-Vitamin-D (25OHD) among newly detected subjects with dyslipidemia for 6 months (2) To study the impact of 25OHD concentrations on the efficacy of statin treatment. This was a prospective, balanced randomized (1:1), open-label, parallel-group study, in apparently healthy Indian adult men (south Asian, 40-60 years). At baseline, serum lipids and 25OHD concentrations were measured. Based on the Adult Treatment Panel III guidelines, subjects were divided as per lipid concentrations into controls (who did not require statin treatment) and intervention (who required statin treatment) groups. Random allocation of subjects was done in two groups for receiving intervention for 6 months: Atorvastatin group (n = 52, received Atorvastatin) or Rosuvastatin group (n = 52, received Rosuvastatin). Lipids and 25OHD concentrations were measured at the end line. Atorvastatin group presented significant reduction (P < 0.05) in 25OHD, total cholesterol (TC) and low-density-lipoprotein-cholesterol (LDL-C) concentrations at the end line. In the Rosuvastatin group, significant drop in TC, LDL-C and high-density lipoprotein cholesterol (concentrations (P < 0.05) was observed, while 25OHD concentrations showed no significant change. Mean 25OHD concentrations were significantly correlated with a reduction in LDL-C concentrations in Atorvastatin group. Treatment with Atorvastatin resulted in a reduction in 25OHD concentrations; further, its efficacy in reducing LDL-C concentrations was related to the 25OHD concentrations.
Sections du résumé
BACKGROUND
BACKGROUND
Dyslipidemias are on the rise and are increasingly being treated with statins. As the metabolism of cholecalciferol and cholesterol are interrelated, reduction in cholesterol synthesis by statins is likely to affect Vitamin D status.
OBJECTIVES
OBJECTIVE
(1) The aim is to study the effect of treatment with statins (Atorvastatin/Rosuvastatin) on 25-hydroxy-Vitamin-D (25OHD) among newly detected subjects with dyslipidemia for 6 months (2) To study the impact of 25OHD concentrations on the efficacy of statin treatment.
MATERIALS AND METHODS
METHODS
This was a prospective, balanced randomized (1:1), open-label, parallel-group study, in apparently healthy Indian adult men (south Asian, 40-60 years). At baseline, serum lipids and 25OHD concentrations were measured. Based on the Adult Treatment Panel III guidelines, subjects were divided as per lipid concentrations into controls (who did not require statin treatment) and intervention (who required statin treatment) groups. Random allocation of subjects was done in two groups for receiving intervention for 6 months: Atorvastatin group (n = 52, received Atorvastatin) or Rosuvastatin group (n = 52, received Rosuvastatin). Lipids and 25OHD concentrations were measured at the end line.
RESULTS
RESULTS
Atorvastatin group presented significant reduction (P < 0.05) in 25OHD, total cholesterol (TC) and low-density-lipoprotein-cholesterol (LDL-C) concentrations at the end line. In the Rosuvastatin group, significant drop in TC, LDL-C and high-density lipoprotein cholesterol (concentrations (P < 0.05) was observed, while 25OHD concentrations showed no significant change. Mean 25OHD concentrations were significantly correlated with a reduction in LDL-C concentrations in Atorvastatin group.
CONCLUSIONS
CONCLUSIONS
Treatment with Atorvastatin resulted in a reduction in 25OHD concentrations; further, its efficacy in reducing LDL-C concentrations was related to the 25OHD concentrations.
Identifiants
pubmed: 33283767
pii: Indian J Pharmacol_2020_52_5_365_302509
doi: 10.4103/ijp.IJP_93_18
pmc: PMC8025761
doi:
Substances chimiques
Cholesterol, HDL
0
Cholesterol, LDL
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Vitamin D
1406-16-2
Rosuvastatin Calcium
83MVU38M7Q
Cholesterol
97C5T2UQ7J
Atorvastatin
A0JWA85V8F
25-hydroxyvitamin D
A288AR3C9H
Types de publication
Comparative Study
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
365-371Déclaration de conflit d'intérêts
None
Références
Hepatology. 2014 Aug;60(2):679-86
pubmed: 24700436
J Am Coll Cardiol. 2004 Aug 4;44(3):720-32
pubmed: 15358046
Lipids Health Dis. 2010 May 21;9:52
pubmed: 20487572
J Cardiovasc Pharmacol Ther. 2013 May;18(3):229-33
pubmed: 23288870
Health Aff (Millwood). 2014 Feb;33(2):273-82
pubmed: 24493771
Ann Intern Med. 2010 Mar 2;152(5):315-23
pubmed: 20194238
Pharmacogenomics J. 2006 Nov-Dec;6(6):360-74
pubmed: 16550210
J Osteoporos. 2014;2014:468397
pubmed: 25197610
Clin Chem. 2010 Nov;56(11):1696-700
pubmed: 20817794
Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):546-53
pubmed: 26425462
Eur Rev Med Pharmacol Sci. 2008 Mar-Apr;12(2):83-8
pubmed: 18575157
J Clin Densitom. 2000 Spring;3(1):35-41
pubmed: 10745300
Nutrients. 2014 Feb 21;6(2):729-75
pubmed: 24566435
Atherosclerosis. 2011 Aug;217(2):308-21
pubmed: 21762916
Mol Nutr Food Res. 2011 May;55(5):691-702
pubmed: 21280209
J Lipid Res. 2009 Apr;50(4):730-9
pubmed: 19043140
Cardiovasc Drugs Ther. 2009 Aug;23(4):295-9
pubmed: 19543962
Acta Derm Venereol. 2011 Mar;91(2):115-24
pubmed: 21384086
Clin Pharmacokinet. 2003;42(13):1141-60
pubmed: 14531725
QJM. 2012 May;105(5):487-91
pubmed: 22323613
Ann Intern Med. 2010 Mar 2;152(5):307-14
pubmed: 20194237
Am J Physiol Gastrointest Liver Physiol. 2008 Apr;294(4):G839-43
pubmed: 18276831
J Clin Endocrinol Metab. 2005 Feb;90(2):1210-9
pubmed: 15546903
Cardiovasc Ther. 2011 Apr;29(2):146-52
pubmed: 20370794
Open Cardiovasc Med J. 2014 Jul 11;8:55-60
pubmed: 25110531
J Assoc Physicians India. 2009 Jan;57:40-8
pubmed: 19753759
PLoS One. 2014 Feb 19;9(2):e88877
pubmed: 24586424
Indian J Med Res. 2010 Nov;132:561-6
pubmed: 21150008
Clin Ther. 2003 Oct;25(10):2553-63
pubmed: 14667956